Literature DB >> 19383884

Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study.

Catherine Ibarra-Drendall1, Lee G Wilke, Carola Zalles, Victoria Scott, Laura E Archer, Siya Lem, Lisa D Yee, Joanne Lester, Swati Kulkarni, Christine Murekeyisoni, Marie Wood, Karen Wilson, Judy Garber, Carleen Gentry, April Stouder, Gloria Broadwater, Joseph C Baker, Shauna N Vasilatos, Elizabeth Owens, Sarah Rabiner, Abbey C Barron, Victoria L Seewaldt.   

Abstract

BACKGROUND: Random periareolar fine needle aspiration (RPFNA) is a research technique developed to assess short-term breast cancer risk in women at increased risk of breast cancer. Although there is increasing acceptance of RPFNA, neither the reproducibility nor the inter-institutional compatibility of RPFNA has been established. To address these key limitations, the Cancer and Leukemia Group B (CALGB) Prevention Group tested the reproducibility of RPFNA in a multi-institutional cross-sectional study.
METHODS: Sixty-three high-risk women from five CALGB institutions (Duke, Ohio State, Roswell Park, Dana Farber, and Vermont) underwent RPFNA from July 1, 2007 to June 30, 2008. Duplicate bilateral RPFNA was performed on each woman by a single investigator on a single day. Masood Cytology Index score was assessed by a single blinded cytopathologist.
RESULTS: There was a high degree of statistical agreement in the Masood Cytology Index scores of duplicate RPFNA samples from the same breast, with a Spearman correlation coefficient of 0.8312 (P < 0.0001). Importantly, although there was agreement in duplicate samples from the same breast, there was lack of agreement between duplicate samples from the opposite breast.
CONCLUSIONS: This multi-institutional study shows that RPFNA is a highly reproducible measure of breast cytology in a cooperative group cross-sectional trial. RPFNA did not show a high degree of agreement between breasts, suggesting that breast cancer risk and progression may occur at different rates in individual breasts from a single woman. These studies provide proof-of-principle for future RPFNA-based cooperative group prevention studies.

Entities:  

Mesh:

Year:  2009        PMID: 19383884      PMCID: PMC3640981          DOI: 10.1158/1055-9965.EPI-08-1210

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  27 in total

1.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

2.  Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.

Authors:  Gregory R Bean; Catherine Ibarra Drendall; Vanessa K Goldenberg; Joseph C Baker; Michelle M Troch; Carolyn Paisie; Lee G Wilke; Lisa Yee; Paul K Marcom; Bruce F Kimler; Carol J Fabian; Carola M Zalles; Gloria Broadwater; Victoria Scott; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01       Impact factor: 4.254

3.  Biomarkers in benign breast disease: risk factors for breast cancer.

Authors:  D C Allred; S G Hilsenbeck
Journal:  J Natl Cancer Inst       Date:  1998-09-02       Impact factor: 13.506

4.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Authors:  Wenle Xia; Sarah Bacus; Priti Hegde; Intisar Husain; Jay Strum; Leihua Liu; Georgina Paulazzo; Ljuba Lyass; Patricia Trusk; Jason Hill; Jennifer Harris; Neil L Spector
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

5.  Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19-25 years who were first and/or second degree relatives to breast cancer patients.

Authors:  H C Jernström; H Olsson; A Borg
Journal:  Eur J Cancer Prev       Date:  1997-08       Impact factor: 2.497

6.  A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.

Authors:  Carol J Fabian; Bruce F Kimler; Deborah A Brady; Matthew S Mayo; C H Joseph Chang; John A Ferraro; Carola M Zalles; Annette L Stanton; Shahla Masood; William E Grizzle; Norman F Boyd; Dora W Arneson; Karen A Johnson
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

7.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

Authors:  T R Rebbeck; A M Levin; A Eisen; C Snyder; P Watson; L Cannon-Albright; C Isaacs; O Olopade; J E Garber; A K Godwin; M B Daly; S A Narod; S L Neuhausen; H T Lynch; B L Weber
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

8.  ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Authors:  Joseph C Baker; Julie H Ostrander; Siya Lem; Gloria Broadwater; Gregory R Bean; Nicholas C D'Amato; Vanessa K Goldenberg; Craig Rowell; Catherine Ibarra-Drendall; Tracey Grant; Patrick G Pilie; Shauna N Vasilatos; Michelle M Troch; Victoria Scott; Lee G Wilke; Carolyn Paisie; Sarah M Rabiner; Alejandro Torres-Hernandez; Carola M Zalles; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

9.  Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.

Authors:  Vanessa K Goldenberg; Victoria L Seewaldt; Victoria Scott; Gregory R Bean; Gloria Broadwater; Carol Fabian; Bruce Kimler; Carola Zalles; Isaac M Lipkus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-05       Impact factor: 4.254

10.  Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer.

Authors:  Qamar J Khan; Bruce F Kimler; Anne P O'Dea; Carola M Zalles; Priyanka Sharma; Carol J Fabian
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  8 in total

1.  Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside.

Authors:  Carol J Fabian; Bruce F Kimler; Carola M Zalles; Jennifer R Klemp; Brian K Petroff; Qamar J Khan; Priyanka Sharma; Kenneth D R Setchell; Xueheng Zhao; Teresa A Phillips; Trina Metheny; Jennifer R Hughes; Hung-Wen Yeh; Karen A Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-19

2.  Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.

Authors:  Catherine Ibarra-Drendall; Michelle M Troch; William T Barry; Gloria Broadwater; Emanuel F Petricoin; Julia Wulfkuhle; Lance A Liotta; Siya Lem; Joseph C Baker; Anne C Ford; Lee G Wilke; Carola Zalles; Nicole M Kuderer; Abigail W Hoffman; Melanie Shivraj; Priya Mehta; Jamila Williams; Nora Tolbert; Laurie W Lee; Patrick G Pilie; Dihua Yu; Victoria L Seewaldt
Journal:  Breast Cancer Res Treat       Date:  2011-06-07       Impact factor: 4.872

3.  Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.

Authors:  Patrick G Pilie; Catherine Ibarra-Drendall; Michelle M Troch; Gloria Broadwater; William T Barry; Emanuel F Petricoin; Julia D Wulfkuhle; Lance A Liotta; Siya Lem; Joseph C Baker; April Stouder; Anne C Ford; Lee G Wilke; Carola M Zalles; Priya Mehta; Jamila Williams; Melanie Shivraj; Zuowei Su; Joseph Geradts; Dihua Yu; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-17       Impact factor: 4.254

4.  Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women.

Authors:  Carol J Fabian; Bruce F Kimler; Joseph E Donnelly; Debra K Sullivan; Jennifer R Klemp; Brian K Petroff; Teresa A Phillips; Trina Metheny; Sonya Aversman; Hung-Wen Yeh; Carola M Zalles; Gordon B Mills; Stephen D Hursting
Journal:  Breast Cancer Res Treat       Date:  2013-10-19       Impact factor: 4.872

5.  Gene expression in breast and adipose tissue after 12 months of weight loss and vitamin D supplementation in postmenopausal women.

Authors:  Larissa A Korde; Anne McTiernan; Caitlin Mason; Lei Wang; Catherine Duggan; Ikuyo Imayama; Sushma S Thomas; Ching-Yun Wang
Journal:  NPJ Breast Cancer       Date:  2017-04-21

6.  Epigenetic Dysregulation of KCNK9 Imprinting and Triple-Negative Breast Cancer.

Authors:  David A Skaar; Eric C Dietze; Jackelyn A Alva-Ornelas; David Ann; Dustin E Schones; Terry Hyslop; Christopher Sistrunk; Carola Zalles; Adrian Ambrose; Kendall Kennedy; Ombeni Idassi; Gustavo Miranda Carboni; Michael N Gould; Randy L Jirtle; Victoria L Seewaldt
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.575

7.  Comparison of Random Periareolar Fine Needle Aspirate versus Ductal Lavage for Risk Assessment and Prevention of Breast Cancer.

Authors:  Abigail Hoffman; Rod Pellenberg; Catherine Ibarra Drendall; Victoria Seewaldt
Journal:  Curr Breast Cancer Rep       Date:  2012-06-22

Review 8.  Random periareolar fine-needle aspiration: the new pap smear of the breast?

Authors:  Joanne Lester; Lisa Diane Yee
Journal:  J Adv Pract Oncol       Date:  2012-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.